Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus Anti-CD20 vs Lenalidomide plus Rituximab in R/R FL or MZL
NCT05100862Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Mar 2022
- Primary completion
- Jul 2028
- Countries
- 28
01
Overview
A Phase 3 trial of zanubrutinib in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by BeOne Medicines. Started Mar 2022; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05100862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100862.